Check Before You Invest : Concord Biotech Ltd

Snapshot

Q.1 Which industry/sub-sector does Concord Biotech Ltd belong to?

Concord Biotech Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.

Q.2 Is Concord Biotech Ltd a good quality company?

Concord Biotech Ltd is a good quality company, based on a consistently good 6-year financial track record.

Q.3 Is Concord Biotech Ltd undervalued or overvalued?

Concord Biotech Ltd appears Somewhat Undervalued, as its key valuation ratios are below with their past averages.

Q.4 Is Concord Biotech Ltd a good buy now?

Concord Biotech Ltd is a good buy now, based on strong price trend analysis suggesting prices may rise. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Concord Biotech Ltd?

Concord Biotech Ltd revenue growth is 18% for FY-2025, which is below its 5-year CAGR of 18.56%, indicating slower growth.

Q.2 Return on capital employed (ROCE) of Concord Biotech Ltd?

Concord Biotech Ltd Return on capital employed is 29.62% for FY-2025, which is in line with its 5-year historical median of 29.13%. The current ROCE is above its estimated weighted average cost of capital (WACC) of 13.5%, indicating value creation.

Q.3 Return on Asset of Concord Biotech Ltd?

Concord Biotech Ltd Return on Asset is 19.9%, which is in line with its 5-year historical median of 19.17%, indicating stable asset utilization efficiency.

Q.4 Return on Equity (ROE) of Concord Biotech Ltd?

Concord Biotech Ltd Return on equity is 22.26% for FY-2025, which is in line with its 5-year historical median of 21.88%, indicating the business is making similar use of its shareholders capital.

Q.5 Cash conversion cycle of Concord Biotech Ltd?

Concord Biotech Ltd Cash conversion cycle is 146 days, above its 5-year historical median of 131 days, indicating deteriorated working capital management. However, you need to compare this with its peers in the industry.

	Current Level	5-year Historic Median
Asset Turnover	0.64	0.57
ROE	22.26	21.88
ROCE	29.62	29.13
Cash Conversion Cycle	146 days	131 days

Q.6 Gross Profit margin of Concord Biotech Ltd?

Concord Biotech Ltd Gross profit margin which is the profit after deduction of direct costs, is 45.9% for FY-2025, which is in line with its 5-year median of 45.5%, indicating stable margins.

Q.7 Operating Profit Margin of Concord Biotech Ltd?

Concord Biotech Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 42.25% for FY-2025, which is in line with its 5-year median of 42.25% indicating stable margins.

Q.8 Net Profit Margin of Concord Biotech Ltd?

Concord Biotech Ltd Net Profit Margin is 30.97% for FY-2025, is in line with with its 5-year median of 30.3%, indicating stable margins.

	Current Level	5-year Historic Median
Gross Profit Margin	45.9	45.5
Operating Profit Margin	42.25	42.25
Net Profit Margin	30.97	30.3

Q.9 Debt to Equity ratio of Concord Biotech Ltd?

Concord Biotech Ltd Debt-to-Equity ratio is 0.00, which is lower with the industry average of 0.27, indicating lower debt levels in the industry.

Q.10 Debt to cash flow from operations of Concord Biotech Ltd?

Concord Biotech Ltd Debt to cash flow from operations is 0, which is at a healthy level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Concord Biotech Ltd?

Promoters hold 44.08% of the Concord Biotech Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Concord Biotech Ltd vs industry peers?

Concord Biotech Ltd revenue CAGR is 18.56%, compared to the industry median CAGR of 8.30%, indicating faster growth and gaining its market share.

Profit Metrics

	Current Level	5-year Industry Median
Revenue Growth	18	8.3
Gross Profit Growth	18.8	14.7
Operating Profit Growth	17.4	11.4
Net Profit Growth	20.8	NAN

Operating Efficiency

	Current Level	5-year Industry Median
Asset Turnover	0.64	0.81
ROE	22.26	9.49
ROCE	29.62	11.91
Cash Conversion Cycle (days)	145.81	85

Valuation & price assessment

Q.1 Stock return of Concord Biotech Ltd over the last decade?

Over the last 1 year(s), the stock has delivered a CAGR of -13.02% based on the current price.

Q.2 What return has the stock given over the last decade?

	9Y	5Y	3Y	1Y
Share Price CAGR	-	-	-	-13%

Q.3 Valuation ratios of Concord Biotech Ltd vs historical?

The current P/E is lower that its historical median.

Q.4 How do the current valuation ratios compare with 5-year historical median and industry numbers?

Valuation Ratios	Current	5-year Historic Median	5-year Industry Median
Price to Earnings	39.66	53.51	31.09
Price to Book	6.55	10.08	2.85
Price to Sales	10.7	15.47	2.79
EV to EBITDA	25.48	33.96	15.87

Check more companies

5. Wockhardt

8. Pfizer

10. Neuland Laboratories

Check trending companies

1. Zen Technologies Ltd.

2. Syngene International Ltd.

3. Cyient Ltd.

4. Vodafone Idea Ltd.

5. SRF Ltd.